PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-11.20%
Negative revenue growth while CVE stands at 2.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-18.65%
Negative gross profit growth while CVE is at 157.52%. Joel Greenblatt would examine cost competitiveness or demand decline.
-21.71%
Negative EBIT growth while CVE is at 65.66%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-21.71%
Negative operating income growth while CVE is at 65.66%. Joel Greenblatt would press for urgent turnaround measures.
-60.51%
Negative net income growth while CVE stands at 58.28%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-60.19%
Negative EPS growth while CVE is at 58.97%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-60.13%
Negative diluted EPS growth while CVE is at 58.97%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.95%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-1.13%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
3.19%
Dividend growth above 1.5x CVE's 1.14%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
-49.79%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-90.09%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-27.22%
Negative 10Y revenue/share CAGR while CVE stands at 6.07%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
83.80%
5Y revenue/share CAGR 1.25-1.5x CVE's 69.66%. Bruce Berkowitz would verify if cost efficiency or pricing power supports this advantage.
31.49%
3Y revenue/share CAGR at 50-75% of CVE's 51.95%. Martin Whitman would question if the firm lags behind competitor innovations.
-61.60%
Negative 10Y OCF/share CAGR while CVE stands at 70.58%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
12.84%
Below 50% of CVE's 190.47%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
-23.15%
Negative 3Y OCF/share CAGR while CVE stands at 811.93%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
60.11%
Net income/share CAGR at 50-75% of CVE's 92.81%. Martin Whitman might question if the firm’s product or cost base lags behind.
224.97%
Below 50% of CVE's 603.34%. Michael Burry would worry about a substantial lag vs. the competitor’s profit ramp-up.
5.49%
Below 50% of CVE's 477.36%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
7.74%
Below 50% of CVE's 19.22%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-10.27%
Negative 5Y equity/share growth while CVE is at 12.29%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
139.40%
3Y equity/share CAGR above 1.5x CVE's 35.97%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
-13.80%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
158.81%
5Y dividend/share CAGR at 75-90% of CVE's 192.28%. Bill Ackman wants more robust earnings or a higher payout ratio to match the competitor.
221.47%
Below 50% of CVE's 565.24%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
-3.27%
Firm’s AR is declining while CVE shows 38.52%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
-0.77%
Negative asset growth while CVE invests at 2.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-0.09%
We have a declining book value while CVE shows 4.39%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
6.42%
We have some new debt while CVE reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
2.27%
SG&A declining or stable vs. CVE's 246.48%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.